{"organizations": [], "uuid": "e0d6f4741964c45ba1b8820eefd3856cb4e2b9b5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180510.html", "section_title": "Archive News &amp; Video for Thursday, 10 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/idUSL8N1SH0PT", "country": "US", "domain_rank": 408, "title": "BRIEF-Rovi Updates Status Of The Pivotal PRISMA-3 Study Of DORIA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.699, "site_type": "news", "published": "2018-05-10T13:23:00.000+03:00", "replies_count": 0, "uuid": "e0d6f4741964c45ba1b8820eefd3856cb4e2b9b5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/idUSL8N1SH0PT", "ord_in_thread": 0, "title": "BRIEF-Rovi Updates Status Of The Pivotal PRISMA-3 Study Of DORIA", "locations": [], "entities": {"persons": [{"name": "laboratorios", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "doria", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "doria", "sentiment": "negative"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 10 (Reuters) - LABORATORIOS FARMACEUTICOS ROVI SA :\n* SAID ON WEDNESDAY THAT AN INDEPENDENT DATA MONITORING COMMITTEE HAS RECOMMENDED TO CONTINUE THE CLINICAL TRIAL OF PRISMA-3 STUDY FOR THE ONCE-MONTHLY INJECTABLE FORMULATION OF RISPERIDONE ISM, DORIA, TO TREAT SCHIZOPHRENIA\n* RECOMMENDATION ALSO SAYS THAT AN INCREASE OF THE STUDY SAMPLE SIZE IS NOT NEEDED\n* COMPANY PLANS TO FILE A NEW DRUG APPLICATION (NDA), U.S. REGISTRATION DOSSIER FOR THE FOOD AND DRUG ADMINISTRATION (FDA) IN SECOND HALF OF 2019\nSource text for Eikon:\nFurther company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-10T13:23:00.000+03:00", "crawled": "2018-05-11T13:10:34.000+03:00", "highlightTitle": ""}